Clinical Drug Experience Knowledgebase

Breast Neoplasms (Phase 3)

Carcinoma in Situ (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 3)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Cervical Intraepithelial Neoplasia (Phase 2)

Colorectal Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 2)

Fallopian Tube Neoplasms (Phase 2)

Head and Neck Neoplasms (Phase 2)

Kidney Neoplasms (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Melanoma (Phase 2)

Mesothelioma (Phase 2)

Multiple Myeloma (Phase 2)

Myelodysplastic-Myeloproliferative Diseases (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Ovarian Neoplasms (Phase 3)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Recurrence (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Triple Negative Breast Neoplasms (Phase 1)

Undifferentiated Connective Tissue Diseases (Phase 2)